SCHEMBL6868033

SCHEMBL6868033

O=S(=O)(NC1CCC(Nc2ccnc3cc(Cl)ccc23)CC1)c1cccc2cccnc12

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.56
LMNA P02545 1/20 0.56
MCOLN3 Q8TDD5 1/20 0.56
KMT5B Q4FZB7 2/20 0.55
KMT5C Q86Y97 2/20 0.55
NSD2 O96028 1/20 0.53
KMT2A Q03164 6/20 0.50
MEN1 O00255 5/20 0.50
CYP2D6 P10635 3/20 0.50
CYP2C19 P33261 2/20 0.50
CYP3A4 P08684 1/20 0.50
RECQL P46063 1/20 0.50
MAPK1 P28482 1/20 0.49
KDM4E B2RXH2 1/20 0.48
SLC40A1 Q9NP59 3/20 0.44
ATM Q13315 1/20 0.42
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6868036 1.00 ALDH1A1 (0.56) ALDH1A1LMNAMCOLN3KMT5BKMT5C
SCHEMBL6867912 0.85 KMT5B (0.58) ALDH1A1KMT5BKMT5CNSD2KMT2A
SCHEMBL6867916 0.85 KMT5B (0.58) ALDH1A1KMT5BKMT5CNSD2KMT2A
SCHEMBL6866551 0.85 KMT5B (0.61) ALDH1A1LMNAKMT5BKMT5CNSD2
SCHEMBL6866553 0.85 KMT5B (0.61) ALDH1A1LMNAKMT5BKMT5CNSD2
SCHEMBL6868571 0.85 KMT5B (0.53) ALDH1A1LMNAKMT5BKMT5CNSD2
SCHEMBL6867268 0.85 KMT5B (0.53) ALDH1A1KMT5BKMT5CNSD2KMT2A
SCHEMBL6867265 0.85 KMT5B (0.53) ALDH1A1KMT5BKMT5CNSD2KMT2A
SCHEMBL6868568 0.85 KMT5B (0.53) ALDH1A1LMNAKMT5BKMT5CNSD2
SCHEMBL6871827 0.83 KMT5B (0.58) ALDH1A1KMT5BKMT5CNSD2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US claimed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US claimed
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US disclosed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US disclosed
WO-2003070244-A1 ANTAGONIST OF MELANIN CONCENTRATING HORMONE AND THEIR USES ABBOTT LABORATORIES (US) 2003-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor MCHR1, MCHR2, MC1R ALDH1A1 2373/4885LMNA 3981/4885MCOLN3 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.